How are QURE collar max profit and max loss calculated?

Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the QURE collar priced from the end-of-day chain at a 30-day expiry (ATM IV 90.00%), the computed maximum profit is $211.50 per contract and the computed maximum loss is -$188.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a QURE collar?

The breakeven for the QURE collar priced on this page is roughly $45.89 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current QURE market-implied 1-standard-deviation expected move is approximately 25.80%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current QURE implied volatility affect this collar?

QURE ATM IV is at 90.00% with IV rank near 16.17%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

QURE Collar Strategy

QURE (uniQure N.V.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

QURE (uniQure N.V.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.97B, a beta of 1.00 versus the broader market, a 52-week range of 8.73-71.5, average daily share volume of 2.2M, a public-listing history dating back to 2014, approximately 221 full-time employees. These structural characteristics shape how QURE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.00 places QURE roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a collar on QURE?

A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.

Current QURE snapshot

As of June 30, 2026, spot at $46.11, ATM IV 90.00%, IV rank 16.17%, expected move 25.80%. The collar on QURE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this collar structure on QURE specifically: IV regime affects collar pricing on both sides; compressed QURE IV at 90.00% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 25.80% (roughly $11.90 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated QURE expiries trade a higher absolute premium for lower per-day decay. Position sizing on QURE should anchor to the underlying notional of $46.11 per share and to the trader's directional view on QURE stock.

QURE collar setup

The QURE collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With QURE near $46.11, the first option leg uses a $48.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed QURE chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 QURE shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 100 shares	Stock	$46.11	long
Sell 1	Call	$48.00	$2.70
Buy 1	Put	$44.00	$2.48

QURE collar risk and reward

Net Premium / Debit: -$4,588.50
Max Profit (per contract): $211.50
Max Loss (per contract): -$188.50
Breakeven(s): $45.89
Risk / Reward Ratio: 1.122

Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.

QURE collar payoff curve

Modeled P&L at expiration across a range of underlying prices for the collar on QURE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	-$188.50
$10.20	-77.9%	-$188.50
$20.40	-55.8%	-$188.50
$30.59	-33.7%	-$188.50
$40.79	-11.5%	-$188.50
$50.98	+10.6%	+$211.50
$61.17	+32.7%	+$211.50
$71.37	+54.8%	+$211.50
$81.56	+76.9%	+$211.50
$91.76	+99.0%	+$211.50

When traders use collar on QURE

Collars on QURE hedge an existing long QURE stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.

QURE thesis for this collar

The market-implied 1-standard-deviation range for QURE extends from approximately $34.21 on the downside to $58.01 on the upside. A QURE collar hedges an existing long QURE position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current QURE IV rank near 16.17% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on QURE at 90.00%. As a Healthcare name, QURE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to QURE-specific events.

QURE collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. QURE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move QURE alongside the broader basket even when QURE-specific fundamentals are unchanged. Always rebuild the position from current QURE chain quotes before placing a trade.

Frequently asked questions

What is a collar on QURE?: A collar on QURE is the collar strategy applied to QURE (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With QURE stock trading near $46.11, the strikes shown on this page are snapped to the nearest listed QURE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are QURE collar max profit and max loss calculated?: Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the QURE collar priced from the end-of-day chain at a 30-day expiry (ATM IV 90.00%), the computed maximum profit is $211.50 per contract and the computed maximum loss is -$188.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a QURE collar?: The breakeven for the QURE collar priced on this page is roughly $45.89 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current QURE market-implied 1-standard-deviation expected move is approximately 25.80%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a collar on QURE?: Collars on QURE hedge an existing long QURE stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
How does current QURE implied volatility affect this collar?: QURE ATM IV is at 90.00% with IV rank near 16.17%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.